Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.48 |
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10984155 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL8020771 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL517003 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL5653145 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL9461372 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL3868770 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL9405814 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL1409996 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL1409670 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL9321916 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688724-A1 | UNSATURATED ETHER FRAGRANCE PRECURSORS | Givaudan SA (CH) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024200404-A1 | UNSATURATED ETHER FRAGRANCE PRECURSORS | GIVAUDAN SA (CH) | 2024-10-03 | — | — | WO | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-8940664-B2 | Oil release with polyethylene oxide segment-containing N-lauroyl amino acid-based compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| CN-102325787-B | Novel antibacterial agents for the treatment of gram positive infections | CUBIST PHARM INC | 2014-05-28 | — | — | CN | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2010075215-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075215-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090318381-A1 | Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | COMMON PHARMA | 2009-12-24 | — | — | US | disclosed |
| WO-2003050073-A1 | SUBSTITUTED HYDROXYETHYLAMINES | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5254590-A | Enzyme inhibitors, anticholesterol, treatment of atheroscherosis, dylipidemias | ADIR ET COMPAGNIE (FR) | 1993-10-19 | — | — | US | disclosed |
| US-4493843-A | Indole and indoline carboxylic acid compounds and method of use | MAY & BAKER LIMITED (GB) | 1985-01-15 | — | — | US | disclosed |
| EP-0042298-B1 | INDOLE AND INDOLINE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1984-09-12 | — | — | EP | disclosed |
| EP-0042298-A1 | Indole and indoline derivatives | MAY & BAKER LIMITED (GB) | 1981-12-23 | — | — | EP | disclosed |
| US-4129704-A | Polymerization of vinyl monomers employing a diperoxyester mixture composition prepared by reacting dihydroperoxide and peroxyester forming carbonyl compounds | PENNWALT CORPORATION (US) | 1978-12-12 | — | — | US | disclosed |
| US-4097408-A | FROM DIHYDOPEROXIDE AND CARBONYL COMPOUND, POLYMERIZATION CATALYSTS | PENNWALT CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318381-A1 | Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | FUCA2, UGDH, UGCG | CA1 1027/4885ACE2 1497/4885FFAR1 62/4885 |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CA1 4316/4885ACE2 3918/4885FFAR1 2911/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CA1 4316/4885ACE2 3918/4885FFAR1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.